Materials and methods Patients 45 patients with histologically or

Materials and methods Patients 45 patients with histologically or cytologically confirmed stage IIIB or IV NSCLC received gefitinib as first-line treatment between July 2006 and Oct 2008 at the First Affiliated Hospital of Nanjing Medical University. All of these patients were treated initially and had at least one measurable focus according to standard Response Evaluation Criteria in Solid Tumors (RECIST) [15]. These 45 patients consisted of 19 males

and 26 females with median age around 61.8 years (range: 30-78). 17 patients had Selleck Temozolomide smoking history. In terms of tumor histologic types, the patients included 26 adenocarcinomas, 4 bronchioloalveolar carcinomas, 10 squamous cell carcinomas and 5 adenosquamous carcinomas. According to American Joint Committee on Cancer (AJCC) staging manual, 14 patients were in stage IIIB and 31 patients in stage IV. The Eastern Cooperative Oncology Group Performance Status (ECOG-PS) value was less than 2 in 32 patients, and 3 – 4 in 13 patients (Table 1). All patients provided written informed consent before enrollment. This protocol was approved by the Institutional Review Boards of the participating centers. Table 1 Clinical material and efficacy of the 45 patients Characters

NO. CR, n (%) PR, n (%) SD, n(%) PD, n (%) Gender           Vadimezan mw    Male 19 0 15.8(3) 36.8(7) 47.4(9)    Female 26 0 46.1(12) 38.5(10) 15.4(4) Age(year)              < 70 35 0 34.3(12) 37.1(13) 28.6(10)    ≥70 10 0 30.0(3) 40.0(4) 30.0(3) Smoking status              Smokers 17 0 17.6(3) 41.2(7) 41.2(7)    Non-smokers 28 0 42.9(12) 35.7(10) 21.4(6) Tumor histology              Adeno. 26 0 38.5(10) 42.3(11) 19.2(5)    BAC 4 0 75.0(3) 25.0(1) 0.0(0) Squamous 10 0 10.0(1) 30.0(3) 60.0(6)    Adenosquamous 5 0 20.0(1) 40.0(2) 40.0(2) Stage              IIIb 14 0 28.6(4) 50.0(7) 21.4(3)    IV 31 0 35.4(11) 32.3(10) 32.3(10) Brain metastasis PJ34 HCl 4 0 75.0(3) 25.0(1) 0.0(0) PS value    

         ≤ 2 32 0 37.5(12) 37.5(12) 25.0(8)    3~4 13 0 23.0(3) 38.5(5) 38.5(5) Therapy Gefitinib (AstraZeneca Company) was administered orally 250 mg daily, 28 days as a cycle. The treatment was continued until disease progression or intolerable toxicity. Observation index We conducted a thorough physical examination on each patient to acquaint with the health status (PS method). Blood routine, hepatic and renal function, electrocardiogram, PET/CT or CT were examined. These indexes were reexamined regularly during the trial, and the image examination was performed after the first one cycle. After that, the image examination was conducted once two cycles. The follow-up of patients by telephone or outpatient service for 1 year was performed. Evaluative standards Tumor response was assessed as complete response (CR), partial response (PR), stable disease (SD), or progression disease (PD) in accordance with the standard of RECIST [15].


PubMed 124. Shavit L, selleck chemicals llc Korenfeld R, Lifschitz M, Butnaru A, Slotki I. Sodium bicarbonate versus sodium chloride and oral A-769662 ic50 N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease. J Interv Cardiol. 2009;22:556–63 [II].PubMedCrossRef 125. Krasuski RA, Beard BM, Geoghagan JD, Thompson CM, Guidera SA. Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol. 2003;15:699–702 [II].PubMed 126. Bader BD, Berger ED, Heede MB, Silberbaur I, Duda S, Risler T, et al. What is the best hydration regimen to prevent contrast

media-induced nephrotoxicity? Clin Nephrol. 2004;62:1–7 [II].PubMed 127. Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008;52:599–604.PubMedCrossRef 128. DiMari

J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R. N-acetylcysteine ameliorates ischemic renal failure. Am J Physiol. 1997;272:F292–8 [VI].PubMed 129. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004;148:422–9 [II].PubMedCrossRef 130. Azmus AD, Gottschall C, Manica A, Manica J, Duro K, Frey M, et al. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invasive Cardiol. selleck 2005;17:80–4 [II].PubMed 131. Marenzi G, Assanelli

E, Marana I, Lauri G, Campodonico J, Grazi M, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773–82 [II].PubMedCrossRef 132. Investigators ACT. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124:1250–9 Rucaparib [II].CrossRef 133. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008;148:284–94 [I].PubMedCrossRef 134. Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med. 2009;122(874):e9–15 [I].PubMed 135. Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J. 2006;151:140–5 [I].PubMedCrossRef 136. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004;65:1366–74 [I].PubMedCrossRef 137. Kshirsagar AV, Poole C, Mottl A, Shoham D, Franceschini N, Tudor G, et al.

RN carried out some of the taxonomic analyses DE performed the F

RN carried out some of the taxonomic analyses. DE performed the FAME analysis. EK constructed the phylogenetic trees and helped in the final version of the manuscript. AS, LSvanO and JDvanE designed the sampling strategy, collaborated in the data analyses and revised the manuscript. All authors read and approved the final LDC000067 order manuscript.”
“Background As the sole producers of biogenic methane, methanogenic Archaea (methanoarchaea) are a unique and poorly

understood group of microorganisms. Methanoarchaea represent some of the most oxygen sensitive organisms identified to date [1], yet many methanogens can withstand oxygen exposure and resume growth once anaerobic conditions have been restored [2–4]. Thus, methanogens must have effective mechanisms for sensing and responding to redox changes in their local environment. Many methanogenic genomes encode homologues of proteins like superoxide dismutase, alkylhydroperoxide reductase, superoxide reducatase, and rubrerythrins that are known to combat oxidative stress

in anaerobes [5–7]. Thus, methanogens potentially have several mechanisms for mitigating the damage caused by temporary oxidative stress. A better understanding of the oxidative stress response in methanogens is important for understanding their contributions to the CBL0137 cell line planetary Cilengitide in vivo ecosystem. At least one methanogenic protein, F420H2 oxidase, has been shown to reduce O2 to H2O [8]. In Methanothermobacter thermautotrophicus, F420H2 oxidase is the product of fpaA (MTH1350) whose promoter, P fpaA , is regulated by the methanogen-specific V4R domain regulator (MsvR). M. thermautotrophicus MsvR (MthMsvR) and its homologues are unique to a subset of methanogens, including the Methanomicrobiales and Methanosarcinales[9]. Besides controlling expression of fpaA, MthMsvR has also been shown to regulate its own expression at the

transcriptional level in vitro. In its reduced state, MthMsvR represses transcription of fpaA and msvR by abrogating the Mannose-binding protein-associated serine protease binding of general transcription factors at the promoter, P fpaA or P msvR , respectively [9]. Except for the use of a bacterial-like regulator, the basal transcriptional machinery of methanogens and all Archaea resembles that of eukaryotes. The multi-subunit RNA polymerase (RNAP) in Archaea resembles the eukaryotic RNAP II complex and is recruited to the promoter by homologues of the eukaryotic TATA binding protein (TBP) and TFIIB (TFB in Archaea). Archaeal transcription regulators can possess either activator or repressor functions and a few rare examples possess both functions [10]. The only clearly defined activation mechanism to date involves recruitment of TBP to the promoter [11], while archaeal repressors bound near the promoter have been shown to repress transcription in several ways, including abrogation of TBP/TFB or RNA polymerase binding to the promoter [10].

Contrary to these reports, functional characterization of hydroph

Contrary to these reports, functional characterization of hydrophobins in Fusarium verticilloides does not indicate a role of these proteins in growth, infection or mycelium hydrophobicity [12]. Similar results are reported for Botrytis cinerea where deletion mutants of hydrophobin genes does not display any phenotypic differences compared to the wild type (WT) strain [13]. The fungus Clonostachys rosea is a ubiquitous soil borne ascomycete known for its antagonistic abilities against a wide range of plant pathogens [14–18], and for its entomopathogenic and check details nematophagous behaviour [19–21]. The modes of

action of C. rosea as a biological control agent (BCA) are not fully known, although mycoparasitism, competition for nutrients, and secondary metabolite production are suggested to play significant roles [14, 18, 22]. Furthermore, C. rosea can rapidly colonize outer and inner root surfaces (epidermal and cortical cells) of plants like carrot, barley, cucumber and wheat [23, 24], which results in induced defence responses [25]. Hydrophobins in mycoparasitic Trichoderma spp,

are suggested to be involved in hyphal development, sporulation, and plant root attachment and colonization [26–28]. The current study aims to understand the biological function of hydrophobins in C. rosea with emphasis on its role in fungal growth and development, antagonism, and interactions with plants. Our results showed induced expression of C. rosea Hyd1, Hyd2 and Hyd3 in dual cultures during self interaction in comparison to interaction selleck kinase inhibitor with the phytopathogenic fungi B. cinerea and F. graminearum. In addition, Hyd1 showed significant upregulation in conidiating mycelium, although a basal expression of C. rosea Hyd1, Hyd2 and Hyd3 was observed in all conditions tested. By generating individual Hyd1 and Hyd3 deletion (ΔHyd1; ΔHyd3), complementation (ΔHyd1+; ΔHyd3+) and Hyd1, Hyd3 double deletion (ΔHyd1ΔHyd3) strains, we probed the roles of two

C. rosea hydrophobins in conidial hydrophobicity and plant root colonization. Results Identification and phylogenetic analysis of C. rosea hydrophobins Blast searches MRIP against a C. rosea strain IK726 draft genome Vistusertib database using a total of 35 class I, class Ia (the intermediate class) and class II hydrophobin amino acid sequences from Trichoderma spp. [29], identified three genes with an E-value ≤ 1 × 10-5. The presence of additional hydrophobin gene/s in C. rosea genome cannot be excluded, as the short hydrophobin genes may be problematic to predict. Identification of start and stop codons, determination of exon-intron boundaries and open reading frames (ORFs) were done manually, and were further validated by cDNA sequencing. The resulting genes were named Hyd1, Hyd2 and Hyd3. The Hyd1, Hyd2 and Hyd3 sequences are submitted to GenBank with accession numbers KF834267, KF834268, KF834269, respectively.

Eur Heart J 2006;27:1038–47 PubMedCrossRef 8 Cannon CP, Husted

Eur Heart J. 2006;27:1038–47.PubMedCrossRef 8. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, CH5424802 molecular weight and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844–51.PubMedCrossRef 9. Wallentin L, Becker RC, Budaj A,

et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.PubMedCrossRef 10. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute LY3039478 cost myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2569–619.PubMedCrossRef 11. NewsRx. Medication Compliance: 40% of American adults report difficulty in swallowing pills. http://​www.​newsrx.​com/​newsletters/​Biotech-Business-Week/​2004-02-09/​02092004333452BB​.​html. Accessed 18

April 2013. 12. Carnaby-Mann G, Michael Crary M. Pill swallowing by adults with dysphagia. Arch Otolaryngol Head Neck Surg. 2005;131:970–5.PubMedCrossRef 13. Strachan I, Greener M. Medication-related swallowing difficulties may be more common than we realise. Pharm Pract. 2005;15:411–4. 14. White R, Bradnam V. Handbook of drug administration via enteral feeding tubes. http://​www.​pharmacy.​cmu.​ac.​th/​unit/​unit_​files/​files_​download/​2012-03-26HandbkOfDrugAd​miniViaEnteralFe​edingTubes%20​1stEd_​WhiteAndBradn.​pdf VX-689 cost Accessed 16 Jan 2013. 15. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised, placebo-controlled trial. Lancet. 2005;366:1607–21.PubMedCrossRef 16. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral

P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary Endonuclease syndromes. J Am Coll Cardiol. 2007;50:1852–6.PubMedCrossRef 17. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009;157:599–605.PubMedCrossRef 18. AstraZeneca. Data on file: clinical study D5130C00055. 19. AstraZeneca. Data on file: AstraZeneca formulation development report–taste prediction of ticagrelor by an electronic tongue.”
“1 Introduction While the number of hypertensive patients is increasing in most countries because of longevity and unhealthy lifestyles, the control rate of hypertension remains low in many countries, such as China.

Phenetic analysis confirmed that the

BoNT/G complex of pr

Phenetic analysis confirmed that the

BoNT/G complex of proteins shared the most similarity with the/B serotype (Figure 3C-E), as previously reported [10, 23]. To determine the extent of/G’s homology to the/B toxin serotype, we completed an in-depth comparison of six/B subtypes, 22 different accession numbers (Figure 3B, additional files 2). The comparison of individual domains–translocation domain, binding domain NT, binding domain CT, and peptidase–revealed the area of the toxin in which/G shares the greatest (translocation domain) and least (binding domain CT) similarity. Overall, each domain compared, between the two toxins, is greater than 50% similar. This comparison helped to determine which substrate peptide would be optimal to test the activity of/G. selleck Although there are no direct indications that sequence similarity would imply overall identical functionality, click here similar sequences would allow similar crystal structures to form, suggesting similar functionality [24]. It is currently known that both BoNT/B and/G cleave the Synaptobrevin protein;/B cleaves a Gln76-Phe77 bond and/G an Ala81-Ala82 bond five amino acids downstream (Table 1). Because the cleavage

sites of both toxins are relatively near one another–thus the similarity of their binding domain sequences and therefore structures–the same peptide substrate currently used to test/B activity was used to test/G activity Rapamycin nmr [19]. In order to confirm that the commercial BoNT/G complex was active and therefore could be considered analogous to the toxin complex found in clinical samples, various dilutions of the commercial toxin were tested using the Endopep-MS method previously described (Figure 6) [19]. In addition to confirming the toxin’s activity, the Endopep-MS experiments indicated a new optimum temperature for/G activity. When reactions were pulsed at 47°C for 10 min, followed by incubation at 42°C for at least eight hours–as opposed to 37°C for a minimum of 17 hr–an increase in activity and in the quality of mass spectra produced was observed. Other serotypes of BoNT (/C and/D) are often associated with botulism in animals,

avians, equines, and bovines, whose body temperatures are higher than those of humans. BoNT/G has yet to be associated with botulism in a particular organism; however, it is possible that/G would be more effective at causing disease in an organism with a higher body temperature than that of humans, similar to BoNT/C and/D. Figure 6 Endopep-MS method confirmation of commercial BoNT/G activity. This is a representative spectrum indicating BoNT/G activity on a specific substrate peptide. 1Intact substrate, 2C-Terminus product mass 1762.9, and 3N-Terminus product mass 2281.8. The sequences are listed in Table 1. *Indicates double charged ion of the intact substrate peptide. Proteomic strategies and analyses used in this study were important to help define the characteristics of proteins associated with the BoNT/G complex.

J Infect Dis 1985,152(5):985–989 PubMedCrossRef 14 Schachter J:

J Infect Dis 1985,152(5):985–989.PubMedCrossRef 14. Schachter J: Chlamydial infections (first of three parts). N Engl J Med 1978,298(8):428–435.PubMedCrossRef 15. Klint M, Fuxelius H-H, Goldkuhl RR, Skarin H, Rutemark C, SNX-5422 in vitro Andersson SGE, Persson K, Herrmann B: High-resolution genotyping of Chlamydia trachomatis strains by multilocus sequence analysis. J Clin Microbiol 2007,45(5):1410–1414.PubMedCrossRef 16. Christerson L, Ruettger A, Gravningen K, Ehricht R, Sachse K, Herrmann B: High-resolution genotyping of Chlamydia trachomatis by use of a novel multilocus typing DNA microarray. J Clin Microbiol 2011,49(8):2838–2843.PubMedCrossRef 17. Wang Y, Skilton

RJ, Cutcliffe LT, Andrews E, Clarke IN, Marsh P: Evaluation of a high resolution genotyping method for Chlamydia trachomatis using 3Methyladenine routine clinical samples. PLoS One 2011,6(2):e16971.PubMedCrossRef 18. Nunes A, Borrego MJ, Gomes JP: Genomic features beyond Chlamydia trachomatis phenotypes: What do we think we know? Infect Genet Evol 2013, 16C:392–400.CrossRef 19. Fehlner-Gardiner C, Roshick C, Carlson JH, Hughes S, Belland RJ, Caldwell HD, McClarty G: Molecular basis defining human Chlamydia trachomatis tissue tropism. A possible role for tryptophan synthase. J Biol Chem 2002,277(30):26893–26903.PubMedCrossRef 20. Caldwell HD, Wood H, Crane

D, Bailey R, Jones RB, Mabey D, Maclean I, Mohammed Z, Peeling R, Roshick C, et al.: Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J Clin Invest 2003,111(11):1757–1769.PubMed 21. Suchland RJ, Rockey DD, Bannantine JP, Stamm WE: Isolates of Chlamydia trachomatis that occupy nonfusogenic inclusions lack IncA, a protein localized to the inclusion membrane. Infect Immun 2000,68(1):360–367.PubMedCrossRef 22. Kuo CC, Grayston T: Interaction

of Chlamydia trachomatis organisms and HeLa 229 cells. Infect Immun 1976,13(4):1103–1109.PubMed 23. Suchland Myosin RJ, Rockey DD, Weeks SK, Alzhanov DT, Stamm WE: Development of secondary inclusions in cells infected by Chlamydia trachomatis . Infect Immun 2005,73(7):3954–3962.PubMedCrossRef 24. Srinivasan T, Bruno WJ, Wan R, Yen A, Duong J, Dean D: In vitro recombinants of antibiotic resistant Chlamydia trachomatis strains have statistically more breakpoints than clinical recombinants for the same sequenced loci and exhibit selection at unexpected loci. J Bacteriol 2011,194(3):617–626.PubMedCrossRef 25. Smith GR: Homologous recombination near and far from DNA breaks: alternative roles and contrasting views. Annu Rev Genet 2001, 35:243–274.PubMedCrossRef 26. Baldo L, Bordenstein S, Wernegreen JJ, Werren JH: Widespread recombination throughout Wolbachia genomes. Mol Bio Evol 2006,23(2):437–449.CrossRef 27. Bailey TL, Elkan C: Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol 1994, 2:28–36.

9%) compared with Tau-positive group (54 3%), with


9%) compared with Tau-positive group (54.3%), with

statistical significance (p=0.0299). The results are demonstrated in Table 6. Table 6 Association between Tau expression and response to chemotherapy in MDV3100 mw patients with measurable target lesions according to RECIST scale (n=46) Response to chemotherapy according to RECIST Negative Tau expression (n=11) Positive Tau expression CB-839 (n=35) Mann – Whitney test U n % n % Z P OR (CR+PR) 10 90.9% 19 54.3% 2.17 0.0299 SD+PD 1 9.1% 16 45.7% CR 10 90.9% 18 51.4% 2.09 0.0362 PR – - 1 2.9% SD – - 9 25.7% PD 1 9.1% 7 20% Abbreviations: OR – objective response, CR – complete response, PR- partial

response, SD – stable disease, PD – progression disease. Discussion Currently, the most effective chemotherapy in ovarian cancer, recognized as a gold standard is platinum analogue combined with paclitaxel. About 70% of the patients respond to this regimen. The others potentially could benefit from different drugs. However, no predictive factors are known in ovarian cancer. As far as we are concerned, in our study Tau protein was assessed in the tissues of ovarian cancer for the first time by the use of immunohistochemistry (IHC). Majority of the patients was acknowledged as Tau-positive (74.3%), while AZD3965 research buy 25.6% of

the patients was Tau-negative. The results differ from those achieved in other studies. Rouzier et al. recognized 52% of the breast cancer patients as Tau-negative [4]. Similar proportion (57% of Tau-negative) was demonstrated by Pusztai et al. [8] 30% of the patients with gastric cancer in Mimori et al. study was identified as Tau-negative [9]. Obtained findings indicate that Tau protein expression might differ among cancer sites. In our study, Tau-negative status in primary tumor of ovarian cancer was identified as a predictive factor for paclitaxel-containing chemotherapy. Both groups seem to be well balanced regarding to age, FIGO stage, histological type, performance status and grade (Table 7) so it does not seem that there were any biases Guanylate cyclase 2C in this field although it necessary to remember that our study was conducted retrospectivly, so its value is limited. In univariate analysis median PFS was 12.8 months longer in Tau-negative group (p=0.0355). Among 46 patients with measurable target lesions, those qualified as Tau-negative achieved statistically significant more objective responses according to RECIST criteria in comparison to patients with Tau-positive ovarian cancers (90.9% and 54.3% respectively; p=0.0299).

VGP 89-186) RPdV was supported by the Dutch Technology Foundatio

VGP 89-186). RPdV was supported by the Dutch Technology Foundation STW, applied science division

of NWO and the Technology Program of the Ministry of Economic Affairs, project no. 07063. References 1. de Vries RP, Visser J: Aspergillus enzymes involved in degradation of plant cell wall polysaccharides. Microb Mol Biol SBI-0206965 molecular weight Rev 2001, 65:497–522.CrossRef 2. Witteveen CFB, Busink R, Vondervoort P, Dijkema C, Swart K, Visser J: L-arabinose and D-xylose catabolism in Aspergillus niger. J Gen Microbiol 1989, 135:2163–2171. 3. de Groot MJ, van de Vondervoort PJI, de Vries RP, vanKuyk PA, Ruijter GJ, Visser J: Isolation and characterization of two specific regulatory Aspergillus niger mutants shows antagonistic regulation of arabinan and xylan metabolism. Microbiol 2003, 149:1183–1191.CrossRef 4. de Groot MJ, Prathumpai W, Visser J, Ruijter GJ: Metabolic control analysis of Aspergillus niger L-arabinose catabolism. Biotechnol Prog 2005,

21:1610–1616.CrossRefPubMed 5. de Groot MJL: Regulation and control of L-arabinose catabolism in Aspergillus niger. [http://​www.​click here library.​wur.​nl/​wda/​dissertations/​dis3819.​pdf]PhD thesis Wageningen University, Microbiology 2005. 6. de Vries RP, Flipphi MJ, Witteveen CF, Visser J: Characterisation of an Aspergillus nidulans L-arabitol dehydrogenase mutant. FEMS Microbiol Lett 1994, 123:83–90.CrossRefPubMed 7. Pail M, Peterbauer T, Seiboth B, Hametner learn more C, Druzhinina I, Kubicek CP: The metabolic role and evolution of L-arabinitol 3-mercaptopyruvate sulfurtransferase 4-dehydrogenase of Hypocrea jecorina. Eur J Biochem 2004, 271:1864–1872.CrossRefPubMed 8. Richard P, Londesborough J, Putkonen M, Kalkkinen N: Cloning and expression of a fungal L-arabinitol 4-dehydrogenase gene. J Biol Chem 2001, 276:40631–40637.CrossRefPubMed 9. Seiboth B, Hartl L, Pail M, Kubicek CP: D-Xylose metabolism in Hypocrea jecorina: Loss of the xylitol dehydrogenase step can be partially compensated for by lad1-encoded L-arabinitol-4-dehydrogenase. Eukaryotic Cell 2003, 2:867–875.CrossRefPubMed

10. vanKuyk PA, de Groot MJ, Ruijter GJ, de Vries RP, Visser J: The Aspergillus niger D-xylulose kinase gene is co-expressed with genes encoding arabinan degrading enzymes and is essential for growth on arabinose and xylose. Eur J Biochem 2001, 268:5414–5423.CrossRefPubMed 11. Witteveen CFB, Weber F, Busink R, Visser J: Isolation and characterisation of two xylitol dehydrogenases from Aspergillus niger. Microbiol 1994, 140:1679–1685.CrossRef 12. Pauly TA, Ekstrom JL, Beebe DA, Chrunyk B, Cunningham D, Griffor M, Kamath A, Lee SE, Madura R, Mcguire D, et al.: X-ray crystallographic and kinetic studies of human sorbitol dehydrogenase. Structure 2003, 11:1071–1085.CrossRefPubMed 13. Johansson K, El-Ahmad M, Kaiser C, Jörnvall H, Eklund H, Höög J-O, Ramaswamy S: Crystal structure of sorbitol dehydrogenase. Chemico-Biological Interactions 2001, 132:351–358.CrossRef 14.

Microbiol Rev 1987,51(4):509–518 PubMed 35 de Lorenzo V, Wee S,

Microbiol Rev 1987,51(4):509–518.PubMed 35. de Lorenzo V, Wee S, Herrero M, Neilands JB: Operator sequences of the aerobactin operon of plasmid ColV-K30 binding the ferric uptake regulation (fur) repressor. J Bacteriol 1987,169(6):2624–2630.PubMed 36. Bister BBD, Nicholson GJ, Valdebenito M, Schneider K, Winkelmann G, Hantke K, Süssmuth RD: The structure of salmochelins: C-glucosylated enterobactins of Salmonella enterica. Biometals 2004,17(4):471–481.PubMedCrossRef

37. Moss JE, Cardozo TJ, Zychlinsky A, Groisman EA: The selC-associated SHI-2 pathogenicity island of Shigella flexneri. Mol Microbiol 1999,33(1):74–83.PubMedCrossRef 38. Johnson TJ, Johnson SJ, Nolan LK: Complete DNA sequence of a ColBM plasmid from avian pathogenic Escherichia coli suggests

that it evolved from closely MK-1775 order related ColV virulence plasmids. J Bacteriol 2006,188(16):5975–5983.PubMedCrossRef 39. Rodriguez-Siek KE, Giddings CW, Doetkott C, Johnson TJ, Fakhr MK, Nolan LK: Comparison ACP-196 of Escherichia coli isolates implicated in human urinary tract infection and avian colibacillosis. Microbiology 2005,151(Pt 6):2097–2110.PubMedCrossRef 40. Skyberg JA, Johnson TJ, Nolan LK: Mutational and transcriptional analyses of an avian pathogenic Escherichia coli ColV plasmid. BMC Microbiol 2008, 8:24.PubMedCrossRef 41. Bidet P, Metais A, Mahjoub-Messai F, Durand L, Dehem M, Aujard Y, Bingen E, Nassif X, Bonacorsi S: Detection and identification by PCR of a highly virulent phylogenetic subgroup among extraintestinal pathogenic Escherichia coli B2 Strains. Appl Environ Microbiol 2007,73(7):2373–2377.PubMedCrossRef 42. Plainvert C, Bidet P, Peigne C, Barbe V, Medigue C, Denamur E, Bingen E, Bonacorsi S: A new O-antigen gene cluster has a key role in the virulence of the Escherichia coli meningitis clone O45:K1:H7. J Bacteriol 2007,189(23):8528–8536.PubMedCrossRef

43. Negre VL, Bonacorsi S, Schubert S, Bidet P, Nassif X, Bingen E: The siderophore receptor IroN, but not the high-pathogenicity 5FU island or the hemin receptor ChuA, contributes to the bacteremic step of Escherichia coli neonatal meningitis. Infect Immun 2004,72(2):1216–1220.PubMedCrossRef 44. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002,3(7):Research0034.PubMedCrossRef 45. Le Gall T, Darlu P, Escobar-Paramo P, Picard B, Denamur E: Selection-driven transcriptome polymorphism in Escherichia coli/Shigella species. Genome Res 2005,15(2):260–268.PubMedCrossRef 46. Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. In Bioinformatics Methods and Protocols: Methods in Molecular Biology. Edited by: Krawetz S, Misener S. Selleck MS 275 Humana Press, Totowa, NJ; 2000:365–386. 47. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008,3(6):1101–1108.PubMedCrossRef 48.